Results 31 to 40 of about 487,301 (268)
The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes : control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway [PDF]
, 2013 Organometallic half-sandwich complexes [M(p-cymene)(azo/imino-pyridine)X]+ where M = RuII or OsII and X ═ Cl or I, exhibit potent antiproliferative activity toward a range of cancer cells.
Sadler, P. J. +2 more
core +1 more source
The influence of acupuncture TENS currents on the proliferation of cancer cells tested in vitro
Rehabilitacja Medyczna, 2019 Introduction: Transcutaneous Electrical Nerve Stimulation (TENS) is a very popular, non-pharmacological antianalgetic method. Nonetheless, knowledge on using this method is very limited in the treatment of patients with cancer anamnesis.
Marzena Pełczyńska +3 more
doaj +1 more source
Frontiers in Pharmacology, 2020 Repurposing of medicines has gained a lot of interest from the research community in recent years as it could offer safe, timely, and affordable new treatment options for cancer patients with high unmet needs.
Ciska Verbaanderd +5 more
doaj +1 more source
, 2011 According to the Surveillance Epidemiology and End Results report, 1,479,350 men and women will be diagnosed with and 562,340 will die of cancer of all sites in 2009, indicating that about 40% of the cancer patients do not respond well to current ...
Alexei Vazquez
core +1 more source
Experimental and Molecular Medicine, 2019 Cancer: How a plant metabolite analog suppresses tumor growth A synthetic analog of a chemical found in fruit suppresses tumor growth by targeting an RNA-binding protein (hnRNPA2B1) and preventing the production of a pro-cancer regulatory factor.
Nak-Kyun Soung +21 more
doaj +1 more source
Development of an interfering peptide M1-20 with potent anti-cancer effects by targeting FOXM1
Cell Death and Disease, 2023 Disrupting protein–protein interactions (PPIs) has emerged as a promising strategy for cancer drug development. Interfering peptides disrupting PPIs can be rationally designed based on the structures of natural sequences mediating these interactions ...
Huitong Bu +8 more
doaj +1 more source
Cells, 2018 Most cytotoxic agents have limited efficacy for solid cancers. Cell-cycle phase analysis at the single-cell level in solid tumors has shown that the majority of cancer cells in tumors is not cycling and is therefore resistant to cytotoxic chemotherapy ...
Shuya Yano, Robert M. Hoffman
doaj +1 more source
A Novel Alkylating Agent, Glufosfamide, Enhances the Activity of Gemcitabine In Vitro, In Vivo
Neoplasia: An International Journal for Oncology Research, 2007 Glufosfamide is an alkylating agent consisting of iphosphoramide mustard conjugated to glucose that is currently included in clinical studies of pancreatic cancer.
W. Steve Ammons +4 more
doaj +1 more source
A Multitargeted Approach in the Discovery of an Organorhodium Anticancer Agent Based On Vorinostat as a Potent Histone Deacetylase Inhibitor. [PDF]
, 2020 The combination of more than one bioactive moiety in a mulitargeted anticancer agent may result in synergistic activity of its components. Using this concept, bioorganometallic compounds were designed to feature a metal center, a 2-pyridinecarbothioamide
Reynisson
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta +6 more
wiley +1 more source